Associations between MDMA/ecstasy use and physical health in a US population-based survey sample

被引:4
作者
Jones, Grant [1 ]
Ricard, Jocelyn A. [2 ]
Hendricks, Peter [3 ]
Simonsson, Otto [4 ]
机构
[1] Harvard Univ, Cambridge, MA 02138 USA
[2] Yale Univ, New Haven, CT USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Karolinska Inst, Stockholm, Sweden
关键词
Health; MDMA; NSDUH; psychedelics; POSTTRAUMATIC-STRESS-DISORDER; MEDIATED IMMUNE-RESPONSE; CLASSIC PSYCHEDELIC USE; MDMA ECSTASY; PSILOCYBIN; RISK; 3,4-METHYLENEDIOXYMETHAMPHETAMINE; PERSONALITY; DEPRESSION; MORTALITY;
D O I
10.1177/02698811221127318
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: 3,4-Methylenedioxymethamphetamine (MDMA/"ecstasy") is an empathogen that can give rise to increased pleasure and empathy and may effectively treat post-traumatic stress disorder. Although prior research has demonstrated associations between ecstasy use and favorable mental health outcomes, the associations between ecstasy and physical health have largely been unexplored. Thus, the goal of this study was to examine the associations between ecstasy use and physical health in a population-based survey sample. Method: This study utilized data from the National Survey on Drug Use and Health (2005-2018), a yearly survey that collects information on substance use and health outcomes in a nationally representative sample of U.S. adults. We used multinomial, ordered, and logistic regression models to test the associations between lifetime ecstasy use and various markers of physical health (self-reported body mass index, overall health, past year heart condition and/or cancer, past year heart disease, past year hypertension, and past year diabetes), controlling for a range of potential confounders. Results: Lifetime ecstasy use was associated with significantly lower risk of self-reported overweightness and obesity (adjusted relative risk ratio range: 0.55-0.88) and lower odds of self-reported past year heart condition and/or cancer (adjusted odds ratio (aOR): 0.67), hypertension (aOR: 0.85), and diabetes (aOR: 0.58). Ecstasy use was also associated with significantly higher odds of better self-reported overall health (aOR: 1.18). Conclusion: Ecstasy shares protective associations with various physical health markers. Future longitudinal studies and clinical trials are needed to more rigorously test these associations.
引用
收藏
页码:1129 / 1135
页数:7
相关论文
共 73 条
[11]  
Davis Alan K, 2017, Drug Sci Policy Law, V3, DOI 10.1177/2050324517711069
[12]   Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years [J].
dos Santos, Rafael G. ;
Osorio, Flavia L. ;
Crippa, Jose Alexandre S. ;
Riba, Jordi ;
Zuardi, Antonio W. ;
Hallak, Jaime E. C. .
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2016, 6 (03) :193-213
[13]   Altered energy production, lowered antioxidant potential, and inflammatory processes mediate CNS damage associated with abuse of the psychostimulants MDMA and methamphetamine [J].
Downey, Luke A. ;
Loftis, Jennifer M. .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 727 :125-129
[14]   A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers [J].
Dumont, GJH ;
Verkes, RJ .
JOURNAL OF PSYCHOPHARMACOLOGY, 2006, 20 (02) :176-187
[15]   Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline [J].
Feduccia, Allison A. ;
Jerome, Lisa ;
Yazar-Klosinski, Berra ;
Emerson, Amy ;
Mithoefer, Michael C. ;
Doblin, Rick .
FRONTIERS IN PSYCHIATRY, 2019, 10
[16]   The development of tolerance to drugs that suppress food intake [J].
Fernstrom, John D. ;
Choi, SuJean .
PHARMACOLOGY & THERAPEUTICS, 2008, 117 (01) :105-122
[17]   Cessation and reduction in alcohol consumption and misuse after psychedelic use [J].
Garcia-Romeu, Albert ;
Davis, Alan K. ;
Erowid, Fire ;
Erowid, Earth ;
Griffiths, Roland R. ;
Johnson, Matthew W. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2019, 33 (09) :1088-1101
[18]   Neurochemical and Neurotoxic Effects of MDMA (Ecstasy) and Caffeine After Chronic Combined Administration in Mice [J].
Gorska, Anna Maria ;
Kaminska, Katarzyna ;
Wawrzczak-Bargiela, Agnieszka ;
Costa, Giulia ;
Morelli, Micaela ;
Przewlocki, Ryszard ;
Kreiner, Grzegorz ;
Golembiowska, Krystyna .
NEUROTOXICITY RESEARCH, 2018, 33 (03) :532-548
[19]   Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? [J].
Gouzoulis-Mayfrank, E ;
Daumann, J .
ADDICTION, 2006, 101 (03) :348-361
[20]   Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance [J].
Griffiths, R. R. ;
Richards, W. A. ;
McCann, U. ;
Jesse, R. .
PSYCHOPHARMACOLOGY, 2006, 187 (03) :268-283